Sumary of Q&A: The case for an intranasal COVID-19 vaccine:
- July 22, 2021 2 min read Source/Disclosures Published by: Source: Healio Interview.
- Disclosures: Randall reports being a consultant for and receiving research funding from Altimmune.
- Back to Healio According to scientists from the University of Alabama at Birmingham, only a small number of COVID-19 vaccines in development are given as nasal sprays, despite the technology’s potential to block SARS-CoV-2 transmission at the source.
- it seems surprising that only seven of the nearly 100 SARS-CoV-2 vaccines currently in clinical trials are delivered intranasally,” Frances Lund, PhD, and Troy D.
- Randall, PhD, wrote in a viewpoint published today in Science.
- It may — depending on regulatory approval — mean that vaccines could be administered by oneself or by someone who is not trained to perform intramuscular injections.
- That might make it easier to distribute and administer the vaccines.
- Some aspects of the immune response occur locally, and having immunity in the nose should better protect against respiratory infection.